ABVC Biopharma develops plant-based therapeutics targeting severe illnesses such as major depressive disorder and ADHD, utilizing research from prestigious institutions to advance their drug pipeline. The company focuses on creating safe, all-natural medications that aim to reduce side effects associated with traditional pharmaceuticals.
Funding
$1.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients experience severe illnesses, such as major depressive disorder, ADHD, and certain cancers, which often require treatments with significant side effects. There is a need for safer, more natural therapeutic options that can effectively manage these conditions while minimizing adverse reactions.
Solution
ABVC Biopharma is a biopharmaceutical company that focuses on identifying and commercializing plant-based drugs and medical devices sourced from research institutions. Their pipeline includes botanical products targeting ophthalmology, psychiatric disorders, and oncology. ABVC's approach leverages plant-based medicine to develop therapeutics with potentially fewer side effects compared to traditional pharmaceuticals. The company collaborates with research institutions to advance its portfolio of drug candidates through clinical trials, with the goal of providing safer treatment options for severe illnesses.
Target Audience
The primary target audience includes patients suffering from major depressive disorder, ADHD, specific cancers like triple-negative breast cancer, and those in need of ophthalmological interventions such as vitreous replacement.
Features
- Development of plant-based therapeutics for major depressive disorder (ABV-1504), ADHD (ABV-1505), and depression in cancer patients (ABV-1601).
- Vitargus® (ABV-1701): A biodegradable, next-generation vitreous replacement for ophthalmological applications.
- ABV-2001: Intraocular irrigation solution.
- ABV-2002: Corneal storage media.
- Development of drugs for oncology, including triple-negative breast cancer (ABV-1501), myelodysplastic syndrome (ABV-1702), and pancreatic cancer (ABV-1703).
- Subsidiary BioKey, Inc. provides contract development and manufacturing services for nutritional and pharmaceutical products.